Today: 20 March 2026
Browse Category

NASDAQ:XOMA 22 August 2025

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.

Stock Market Today

  • 3 Worst-Performing Singapore Blue Chips in 2026: Genting Singapore Leads Decline
    March 20, 2026, 8:29 AM EDT. Singapore's stock market faced headwinds in early 2026. Genting Singapore Limited (SGX: G13) emerged as the worst YTD performer among blue chips, with its share price down 8.3% by mid-March. The integrated resort operator's FY2025 net profit plunged 33% year-on-year to S$390.3 million amid a softer gaming recovery and ongoing renovations at Resorts World Sentosa. Gaming segment weakness, intensified competition from Marina Bay Sands, and hotel occupancy challenges weighed on results. Despite a recovering broader gaming market, Genting Singapore's transformation phase and operational disruptions have depressed earnings. The outlook hinges on completion of renovations and stabilizing non-gaming segments. Investors watch for potential turnaround triggers amid income opportunities re-emerging across the Singapore market.
Go toTop